Edwards Lifesciences Corp. (NYSE:EW) shares were down 1.6% during mid-day trading on Friday . The company traded as low as $104.92 and last traded at $105.27, with a volume of 1,636,493 shares changing hands. The stock had previously closed at $107.03.

A number of research analysts have issued reports on EW shares. Goldman Sachs Group Inc. lifted their price objective on Edwards Lifesciences Corp. from $100.00 to $125.00 in a report on Friday, April 8th. Jefferies Group raised their target price on Edwards Lifesciences Corp. from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, April 4th. BTIG Research upgraded Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating and set a $115.00 target price for the company in a research note on Monday, April 4th. Canaccord Genuity raised their target price on Edwards Lifesciences Corp. from $95.00 to $113.00 and gave the company a “buy” rating in a research note on Monday, April 4th. Finally, Stifel Nicolaus lowered their target price on Edwards Lifesciences Corp. from $117.00 to $98.00 and set a “buy” rating for the company in a research note on Monday, April 4th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the stock. Edwards Lifesciences Corp. currently has an average rating of “Buy” and an average price target of $106.14.

The firm has a market cap of $22.29 billion and a price-to-earnings ratio of 44.81. The firm has a 50-day moving average price of $100.77 and a 200-day moving average price of $93.45.

Edwards Lifesciences Corp. (NYSE:EW) last released its earnings results on Tuesday, April 26th. The medical research company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. The business had revenue of $697.30 million for the quarter, compared to analyst estimates of $664.53 million. During the same period in the prior year, the business earned $1.12 EPS. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Corp. will post $2.76 earnings per share for the current fiscal year.

In other Edwards Lifesciences Corp. news, CEO Michael A. Mussallem sold 59,000 shares of the stock in a transaction that occurred on Friday, April 29th. The stock was sold at an average price of $106.13, for a total value of $6,261,670.00. Following the transaction, the chief executive officer now owns 79,256 shares in the company, valued at $8,411,439.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Patrick B. Verguet sold 7,000 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $106.86, for a total value of $748,020.00. Following the completion of the transaction, the vice president now owns 115,107 shares in the company, valued at approximately $12,300,334.02. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in EW. J. Goldman & Co LP purchased a new position in shares of Edwards Lifesciences Corp. during the fourth quarter valued at about $2,097,000. Johnston Asset Management Corp raised its position in shares of Edwards Lifesciences Corp. by 117.4% in the fourth quarter. Johnston Asset Management Corp now owns 364,730 shares of the medical research company’s stock valued at $28,806,000 after buying an additional 196,990 shares during the last quarter. Adams Diversified Equity Fund Inc. raised its position in shares of Edwards Lifesciences Corp. by 100.0% in the fourth quarter. Adams Diversified Equity Fund Inc. now owns 244,000 shares of the medical research company’s stock valued at $19,271,000 after buying an additional 122,000 shares during the last quarter. L & S Advisors Inc raised its position in shares of Edwards Lifesciences Corp. by 93.4% in the fourth quarter. L & S Advisors Inc now owns 55,652 shares of the medical research company’s stock valued at $4,395,000 after buying an additional 26,878 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Edwards Lifesciences Corp. by 101.1% in the fourth quarter. US Bancorp DE now owns 84,952 shares of the medical research company’s stock valued at $6,709,000 after buying an additional 42,708 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.